Month: September 2019

ProMIS Neurosciences to Present at HC Wainwright Investment Conference

Company
to showcase its innovative Alzheimer’s, Parkinson’s and ALS programs

TORONTO and CAMBRIDGE, MA, Sept. 3, 2019 /PRNewswire/ – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its participation in the 21^st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC.  The conference is being held September 8-10, 2019 at the New York Palace Hotel in New York.

ProMIS’ Executive Chairman, Eugene Williams will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS  (amyotrophic lateral sclerosis) Tuesday, September 10^th at 10:25 am ET.  The audio webcast and slides of Mr. Williams’ presentation will be archived and available on ProMIS’ web site and through the following link http://wsw.com/webcast/hcw5/arfxf/.

About ProMIS’ Platform
Technology
Numerous studies show that a common root cause of neurodegenerative diseases is the toxic oligomer, a misfolded protein that derives from naturally occurring proteins in the brain. Using its novel drug discovery platform, ProMIS can uniquely and selectively target the toxic oligomer, filling a critical gap for drug developers as traditional approaches to developing antibodies are unable to isolate and target the toxic oligomer with adequate precision. This proprietary platform can identify targets to produce, test and advance antibody candidates quickly and cost-effectively. ProMIS’ lead candidate antibody, PMN310 for Alzheimer’s disease (AD), demonstrates a high degree of binding to toxic oligomers without binding to non-toxic forms of naturally occurring amyloid beta protein. The company’s program for Parkinson’s disease (PD) is based on the development of several potential antibody therapeutic candidates aimed at selectively targeting toxic oligomers of the protein ?-synuclein, considered a root cause of PD. Similarly, ProMIS has identified antibody candidates selectively targeting toxic oligomers of the protein TDP43, considered a root cause of ALS.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

To learn more, visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn and listen to the podcast, Saving Minds, at iTunes or Spotify.

The TSX has not reviewed and
does not accept responsibility for the adequacy or accuracy of this release.
This information release contains certain forward-looking information. Such
information involves known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be materially
different from those implied by statements herein, and therefore these
statements should not be read as guarantees of future performance or results.
All forward-looking statements are based on the Company’s current beliefs as
well as assumptions made by and information currently available to it as well
as other factors. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. Due to risks and uncertainties, including the risks and uncertainties
identified by the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

View original content to download multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-to-present-at-hc-wainwright-investment-conference-300909802.html

SOURCE ProMIS Neurosciences Inc.

News Provided by PR Newswire via QuoteMedia

Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found on the company’s website.

“These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones will enable us to advance our gene therapy platform and position us to bring our drug candidate to commercialization.”

Anticipated milestones and future guidance:

2H 2019

• Establish scalability parameters of new, optimized manufacturing method for lipid nanoparticle delivery system as part of new Genprex research and development program
• Complete protocol for Oncoprex + immunotherapy clinical trial
• Prepare and file IND for Oncoprex + immunotherapy clinical trial
• Determine clinical site selection, expansion strategy and contract with clinical sites for Oncoprex + erlotinib clinical trial

1H 2020

• Complete manufacturing scale-up to support trial site expansion and commercial-scale development
• Complete preparation of lipid nanoparticle delivery system and TUSC2 DNA plasmid for clinical expansion
• Contract with new clinical trial sites for Oncoprex + immunotherapy clinical trial
• Begin enrolling patients at new clinical sites for Oncoprex + immunotherapy clinical trial

In addition to the milestone updates, Genprex also unveiled in its updated corporate presentation, an overview of the limitations to current NSCLC treatment and a swimmer plot demonstrating results to date of its Phase I/II clinical trial administering Oncoprex in combination with erlotinib against NSCLC. Genprex also recently launched a new interactive timeline on its website where visitors can follow the company’s success since its inception.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our stated milestones and our ability to advance the clinical development, manufacturing and commercialization of our product candidates, and the effects of Oncoprex on cancer. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include our ability to achieve our stated milestones, the timing and effect of our achieving those milestones, and of other factors, on the clinical development, manufacturing and commercialization of our product candidates, the presence and level of TUSC2’s effect on cancer, the timing and success of our clinical trials and planned clinical trials of TUSC2 and Oncoprex™ and our other potential product candidates and the timing and success of obtaining FDA approval of Oncoprex™ and our other potential product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005044/en/

Genprex,
Inc. 
(877) 774-GNPX (4679)

Investor
Relations 
GNPX Investor Relations 
(877) 774-GNPX (4679) ext. #2 
investors@genprex.com

Media
Contact 
Genprex Media Relations 
Kalyn Dabbs 
(877) 774-GNPX (4679) ext. #3 
media@genprex.com

Copyright Business Wire 2019

News
Provided by Business Wire via QuoteMedia